Hadasit Bio Holdings Ltd HSITF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.25
- Day Range
- $0.13–0.13
- 52-Week Range
- $0.00–0.27
- Bid/Ask
- $1.59 / $1.67
- Market Cap
- $1.44 Mil
- Volume/Avg
- 200 / 81,521
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hadasit Bio Holdings Ltd serves as a precedent in the field of biotech financing. It is engaged in the advancement and enhancement of its portfolio companies. Its portfolio companies are involved in the field of medical and biotechnological research and production and distribution of the results of the research and development done in these areas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.hbl.co.il
Valuation
|
Metric
|
HSITF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
HSITF
Financial Strength
|
Metric
|
HSITF
|
|---|---|
Quick Ratio | 3.78 |
Current Ratio | 3.79 |
Interest Coverage | −152.03 |
Quick Ratio
HSITF
Profitability
|
Metric
|
HSITF
|
|---|---|
Return on Assets (Normalized) | −9.17% |
Return on Equity (Normalized) | −11.21% |
Return on Invested Capital (Normalized) | −8.72% |
Return on Assets
HSITF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Trsmyhpmpv | Sjzwk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nclxjwlg | Ccxrbk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ktfpzngp | Gmfmgxf | $99.5 Bil | |
MRNA
| Moderna Inc | Dfgjtdlq | Xrp | $38.8 Bil | |
ARGX
| argenx SE ADR | Bkqxsfzp | Hlgv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pjdcsndj | Mpqg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fcsbycfk | Jtjdgky | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wxptqcgc | Ktxbsc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rnvwcwgqc | Mxsvcb | $12.5 Bil | |
INCY
| Incyte Corp | Fkbqjmxp | Hskds | $11.6 Bil |